This is a clinical milestone update with no new data — the stock is unlikely to move on this news alone. Monitor for topline DURIPANC results in Q1 2027 and OS data in mid-2027, which are the next binary catalysts. The prior Named Patient Program signal is encouraging but exploratory; Phase 2 data will be needed for validation.
Price Chart
Executive Summary
AIM ImmunoTech announced that the final subject received their last dose in the Phase 2 DURIPANC trial of Ampligen for metastatic pancreatic cancer, ahead of schedule. Topline primary endpoint results are anticipated in Q1 2027, with overall survival data expected in mid-2027. The press release highlights encouraging exploratory data from a prior Named Patient Program, but the current filing is a routine clinical trial milestone update with no new efficacy or safety data released.
Key Facts
- Final subject dosed in Phase 2 DURIPANC trial of Ampligen + Imfinzi for metastatic pancreatic cancer ahead of schedule.
- Primary endpoint (Clinical Benefit Rate) analysis to begin December 2026; topline results expected Q1 2027.
- Overall survival endpoint analysis expected to begin June 2027.
- Prior Named Patient Program showed median OS of 34.8 months vs 12.5 months historical control in a biomarker-defined subset (exploratory, not designed for efficacy).
- Company plans to use DURIPANC data to design a pivotal Phase 3 trial.
Financial Impact
No financial data provided in the release. AIM has a market cap of ~$7M.
Risk Factors
- Phase 2 DURIPANC results may not replicate the promising exploratory signal from the Named Patient Program.
- Pancreatic cancer is a difficult indication with high historical failure rates; Ampligen has no approved oncology indication.
- AIM has a very small market cap (~$7M) and limited cash runway — financing risk is elevated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337516 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers